Latest Breaking News On - கிளாரா ஃபெங்கர் - Page 1 : comparemela.com
Kentucky Judge Anxious To Remand Medina Spirit Case To Board Of Stewards - Horse Racing News
paulickreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from paulickreport.com Daily Mail and Mail on Sunday newspapers.
KHRC Alleges Lack Of Candor And Contemptuous Conduct By New York Lab, Baffert Attorneys - Horse Racing News
paulickreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from paulickreport.com Daily Mail and Mail on Sunday newspapers.
Last Comment: May 12, 2021 7:24 am ET | 7 Comment(s) | Jump to Comments
The Kentucky Derby has made headlines across several mainstream media outlets beyond its usual coverage in light of recent news that the winner of the 147th edition, Medina Spirit, received a post-race positive test.
News broke on Sunday (May 9) that a test sample from Medina Spirit showed heightened levels 21 picograms per milliliter of betamethasone, a corticosteroid typically used as an anti-inflammatory for conditions such as arthritis. Said drug is barred by the Kentucky Horse Racing Commission (KHRC) under new protocols passed in 2020 which prohibits administration of any drug or medication within 24 hours of a race. However, its use is allowed under clearance by the KHRC 14 days prior to a race. Bob Baffert, trainer of Medina Spirit, also faced a betamethasone positive in 2020 when his filly Gamine finished third in the Kentucky Oaks, also at Churchill Downs.
The results of the “Clenbuterol plasma concentrations after therapeutic administration in fit Standardbred horses: threshold recommendations” study published online after peer review in
Comparative Exercise Physiology clearly demonstrate and recommend the need for different withdrawal times and threshold levels for harness racing than the current standards that exist for Thoroughbred and Quarter Horse racing.
The goal of this study was to identify a withdrawal time guideline for use of clenbuterol at dose levels approved by the United States Food and Drug Administration (FDA) in harness racing, where horses may start (race) at seven-day intervals.
Three members of the Harness Racing Medication Collaborative Kenneth McKeever, PhD FACSM; George Maylin, DVM, MS, PhD; and Clara Fenger DVM, PhD, DACVIM collaborated on the study.